NasdaqGS - Nasdaq Real Time Price USD

COMPASS Pathways plc (CMPS)

4.7600

+0.0900

+(1.93%)

At close: June 10 at 4:00:01 PM EDT

COMPASS Pathways (CMPS) Upgraded to Buy: Here's What You Should Know

COMPASS Pathways (CMPS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks 27 days ago

CMPS
+1.93%
Compass Pathways to Participate in 2025 RBC Capital Markets Global Healthcare Conference

LONDON & NEW YORK, May 14, 2025--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in a fireside chat at the 2025 RBC Capital Markets Global Healthcare Conference at 10:30 am ET on May 20th, 2025.

Business Wire 27 days ago

CMPS
+1.93%
Psychedelic: Compass, GH Research, MindMed report quarterly earnings

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on earnings, a patent grant and study results. Q1 EARNINGS: On Thursday, Compass Pathways (CMPS) reported a first quarter loss per share of (24c), which compared to analyst estimates of a loss per share of (49c). The company said cash and cash equivalents were $260.1M as of March 31, compared with $165.1M as of December 31. Compass also guided to full year 2025 net cash used in operatin

TipRanks last month

CYBN

GHRS

CMPS
+1.93%
Compass Pathways PLC (CMPS) Q1 2025 Earnings Call Highlights: Pivotal Phase 3 Trial Milestone ...

Compass Pathways PLC (CMPS) advances in treatment-resistant depression trials while maintaining a robust financial position.

GuruFocus.com last month

CMPS
+1.93%
Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights

LONDON & NEW YORK, May 08, 2025--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the first quarter 2025 and provided an update on recent progress across its business.

Business Wire last month

CMPS
+1.93%
Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities

LONDON & NEW YORK, April 29, 2025--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into a strategic collaboration with HealthPort, a multi-site comprehensive community health organization. HealthPort employs an integrated model centered around social determinants of health and this collaboration will help inform the potential delivery of COMP360 synthesized psilocybin treatment in un

Business Wire last month

CMPS
+1.93%
Compass Pathways to Announce First Quarter Financial Results on May 8, 2025

LONDON & NEW YORK, April 28, 2025--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the first quarter ended March 31, 2025, and provide an update on recent developments, on May 8, 2025.

Business Wire last month

CMPS
+1.93%
Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Key Takeaways; Cannabis Sector Tilray announced plans to exit New Zealand medical cannabis market to focus on Australia Village Farms was granted 180-day extension to regain Nasdaq listing requirements SNDL launched “Rise Rewards” loyalty program to boost customer experience Simply Solventless celebrated profitability at Humble Grow Co., surpassing projections Key Takeaways; Psychedelic Sector Cybin expanded […]

Market Exclusive last month

SNDL

TLRY

CMPS
+1.93%
Why Compass Pathways Stock Was a Double-Digit Winner This Week

Such a dynamic was in evidence with U.K.-based Compass Pathways (NASDAQ: CMPS) this week. On news about a step completed in a clinical trial, the company's shares rose by 13% over the period, according to data compiled by S&P Global Market Intelligence. Compass Pathways, which focuses on psilocybin -- the psychoactive compound found in "magic" mushrooms -- announced Tuesday that it had completed dosing in a late-stage clinical trial.

Motley Fool last month

CMPS
+1.93%
Psychedelic: Clearmind completes clinical site initiations for AUD trial

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on site initiations, dosing completion and clinical site partnerships. CLEARMIND COMPLETES SITE INITIATIONS FOR AUD TRIAL: Clearmind Medicine (CMND) announced Wednesday the initiation of its U.S. clinical trial site at the Yale School of Medicine’s Department of Psychiatry. With this initiation, the company has now activated all planned sites for its Phase I/IIa clinical trial in Alcoho

TipRanks last month

CYBN

CMPS
+1.93%

MIRA
Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

LONDON & NEW YORK, April 22, 2025--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that all participants have completed dosing in Part A of the COMP005 phase 3 trial for treatment resistant depression (TRD). Following pre-dosing activities, including washout from anti-depressant medications, if needed, participants received a single dose of either 25 mg of COMP360 or placebo. The Company is on tra

Business Wire last month

CMPS
+1.93%
Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

LONDON & NEW YORK, March 26, 2025--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced the completion of recruitment in the COMP005 phase 3 trial for treatment resistant depression (TRD). The final participants are completing pre-dosing activities, including washout from anti-depressant medications, if necessary, and those eligible will receive a dose of either 25 mg of COMP360 or placebo.

Business Wire 2 months ago

CMPS
+1.93%
Psychedelic: Exclusive talk with biotech company Clearmind Medicine

In this edition of “Psychedelic”, The Fly conducted an exclusive interview with Mark Haden, vice president of business development at Clearmind Medicine (CMND), a psychedelic pharmaceutical biotech company focused on development of therapeutics to solve underserved health problems. Here are some highlights: PSYCHEDELIC PHARMA: Clearmind is a clinical-stage biotech company that aims to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods

TipRanks 2 months ago

CMND

ATAI

GHRS
Psychedelic: atai Life Sciences, NRx report quarterly results

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on earnings, a collaboration LOI and a study publication. EARNINGS: On Monday, atai Life Sciences (ATAI) reported a fourth quarter loss per share of (24c) on revenue loss of ($5,000), which compared to analyst estimates of a loss per share of (15c) and revenue of $18,000 for the same period last year. As of December 31, the company had cash, cash equivalents, restricted cash and short-t

TipRanks 2 months ago

CYBN

ATAI

CMND
Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression

LONDON & NEW YORK, March 18, 2025--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced the publication of results from the COMP004 study, an observational 52-week follow-up from the Phase 2 COMP001 and COMP003 trials of COMP360 psilocybin treatment in patients with treatment-resistant depression (TRD). The COMP004 study's findings suggest that over a 52-week period, a single administration of 25 mg CO

Business Wire 2 months ago

CMPS
+1.93%
Compass Pathways to Participate in Stifel Virtual CNS Forum

LONDON & NEW YORK, March 11, 2025--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the Stifel Virtual CNS Forum at 11:30 am ET on March 18th, 2025.

Business Wire 2 months ago

CMPS
+1.93%
Compass one of the most compelling stories in neuropsych, says H.C. Wainwright

H.C. Wainwright tells investors in a research note that Compass Pathways (CMPS) is one of the most compelling stories in neuropsychiatry, and that COMP360’s differentiated profile positions it as a “transformative” treatment in treatment-resistant depression. The firm believes the current valuation fails to reflect the full scope of its opportunity across multiple large-market psychiatric disorders with COMP360 on track to become a blockbuster treatment, if approved. The firm reiterates a Buy ra

TipRanks 3 months ago

CMPS
+1.93%
COMPASS Pathways plc (CMPS): Among the Best Psychedelic Stocks to Buy in 2025

We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at where COMPASS Pathways plc (NASDAQ:CMPS) stands against the other psychedelic stocks. The Therapeutic Potential and Investment Boom in Psychedelic Medicine In contrast to drugs like cocaine or marijuana, psychedelics are […]

Insider Monkey 3 months ago

CMPS
+1.93%
Psychedelic: GH Research, Compass Pathways report earnings results

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on earnings, an analyst initiation and patent issuance. EARNINGS: On Thursday, GH Research (GHRS) reported a FY24 loss per share of (75c), which compared to analyst estimates of loss per share of (80c). The company also reported cash, cash equivalents, other financial assets and marketable securities at $182.6M as of December 31, compared to cash, cash equivalents, other financial asset

TipRanks 3 months ago

QNTM

ENVB

CYBN
Compass Pathways PLC (CMPS) Q4 2024 Earnings Call Highlights: Strategic Financing and R&D ...

Despite a significant net loss, Compass Pathways PLC (CMPS) secures financing to advance key clinical trials and strengthen its financial position.

GuruFocus.com 3 months ago

CMPS
+1.93%

Performance Overview

Return	CMPS	MSCI WORLD (^990100-USD-STRD)
YTD	+26.93%	+6.14%
1-Year	-27.33%	+13.10%
3-Year	-48.15%	+48.98%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

COMPASS Pathways plc (CMPS)

COMPASS Pathways (CMPS) Upgraded to Buy: Here's What You Should Know

Compass Pathways to Participate in 2025 RBC Capital Markets Global Healthcare Conference

Psychedelic: Compass, GH Research, MindMed report quarterly earnings

Compass Pathways PLC (CMPS) Q1 2025 Earnings Call Highlights: Pivotal Phase 3 Trial Milestone ...

Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights

Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities

Compass Pathways to Announce First Quarter Financial Results on May 8, 2025

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Why Compass Pathways Stock Was a Double-Digit Winner This Week

Psychedelic: Clearmind completes clinical site initiations for AUD trial

Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Psychedelic: Exclusive talk with biotech company Clearmind Medicine

Psychedelic: atai Life Sciences, NRx report quarterly results

Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways to Participate in Stifel Virtual CNS Forum

Compass one of the most compelling stories in neuropsych, says H.C. Wainwright

COMPASS Pathways plc (CMPS): Among the Best Psychedelic Stocks to Buy in 2025

Psychedelic: GH Research, Compass Pathways report earnings results

Compass Pathways PLC (CMPS) Q4 2024 Earnings Call Highlights: Strategic Financing and R&D ...

Performance Overview